35 research outputs found
Prvolinijsko lijeÄenje uznapredovalog raka jajnika: novosti
Ovarian cancer is the fifth most common cause of death among malignant diseases in women in Europe. The standard treatment is cytoreductive surgery, followed by platinum-taxane based chemotherapy. In patients with advanced disease, a valid option is a neoadjuvant chemotherapy followed by interval debulking surgery. Despite the progress in primary treatment, almost 70% of the patients relapse. There is a significant need for better first-line treatment to avoid or delay relapse and improve ovarian cancer outcomes. The most significant change involves the changes in the treatment schedule and new drugs in first-line chemotherapy. Bevacizumab is approved in first-line treatment combined with carboplatin and paclitaxel as it improves progression-free survival (PFS) in patients with a higher risk of recurrence. After achieving the response to first-line chemotherapy, maintenance therapy with poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors prolongs PFS in patients with homologous recombination deficiency (HRD). Patients with BRCA mutations obtain the most significant benefit.Rak jajnika je peti najÄeÅ”Äi uzrok smrti meÄu zloÄudnim bolestima kod žena u Europi. Standardni naÄin lijeÄenja je primarna citoredukcija praÄena kemoterapijom temeljenom na platini i taksanima. Kod bolesnica s uznapredovalom bolesti jedna od opcija lijeÄenja je neoadjuvantna kemoterapija s intervalnom citoredukcijom. UnatoÄ napretku u lijeÄenju, gotovo 70% bolesnica razvije povrat bolesti. Postoji znaÄajna potreba za poboljÅ”anjem prvolinijskog lijeÄenja s ciljem izbjegavanja ili odgaÄanja povrata bolesti i poboljÅ”anja ishoda lijeÄenja bolesnica s rakom jajnika. Najvažnija promjena ukljuÄuje izmjene u naÄinu primjene lijekova i dodavanje novih lijekova prvolinijskoj kemoterapiji. Bevacizumab je odobren u prvolinijskom lijeÄenju u kombinaciji s karboplatinom i paklitakselom zbog poboljÅ”anja preživljenja do napredovanja bolesti (PFS) kod bolesnica s poveÄanim rizikom od recidiva. Terapija održavanja PARP inhibitorima, nakon odgovora na prvolinijsku kemoterapiju,
produljuje PFS kod bolesnica s poremeÄajem u sustavu popravka dvostrukih lomova deoksiribonukleinske kiseline homolognom rekombinacijom. NajveÄu korist imaju bolesnice s BRCA mutacijama
Terapijski pristup seroznom karcinomu jajnika niskog gradusa
Low-grade serous ovarian cancer (LGSOC) has less aggressive behavior and a better clinical outcome than high-grade serous ovarian cancer (HGSOC). Considering that this malignancy is relatively chemoresistant, surgery is the keystone of treatment, with a strong recommendation for maximal cytoreduction. Women with stage IA-IB disease should undergo observation alone after primary cytoreductive surgery. In contrast, observation, chemotherapy, or endocrine therapy are possible options for those with stage IC-IIA disease. Patients with stage IIB-IV disease receive either chemotherapy with carboplatin and paclitaxel for six cycles followed by endocrine therapy, most commonly with aromatase inhibitors, or endocrine therapy alone until disease progression or unacceptable toxicity. Surgery, chemotherapy, and endocrine therapy are also used in patients with recurrent disease. Targeted agents, especially mitogen-activated protein kinase (MEK) inhibitors and cyclin-dependent kinase (CDK) inhibitors, are currently under evaluation in this clinical setting. Additional research on the genomics of LGSOC to better define the activating gene mutations involved in the carcinogenesis is strongly warranted to improve the prognosis with this malignancy.Niskogradusni serozni karcinom jajnika (LGSOC) manje je agresivan i ima bolji kliniÄki ishod u usporedbi s visokogradusnim seroznim karcinomom jajnika (HGSOC). KirurÅ”ko lijeÄenje s pokuÅ”ajem maksimalne citoredukcije važno je i opravdano zbog relativne kemorezistencije ovog tumora. Stadije bolesti IA-IB trebalo bi kliniÄki pratiti nakon primarne citoredukcije, dok su kliniÄko praÄenje, kemoterapija ili hormonska terapija predložene moguÄnosti za stadije bolesti IC-IIA. Bolesnice stadija IIB-IV lijeÄe se kemoterapijom sastavljenom od karboplatina i paklitaksela tijekom 6 ciklusa koju slijedi hormonska terapija, najÄeÅ”Äe inhibitorima aromataze, ili pak samom hormonskom terapijom do progresije bolesti ili neprihvatljive
toksiÄnosti. KirurÅ”ko lijeÄenje, kemoterapija i hormonska terapija takoÄer se koriste za bolesnice s povratom bolesti. U tijeku su kliniÄka istraživanja ciljanom terapijom, posebno s inhibitorima mitogenom-aktiviranih proteinskih kinaza (MEK) i inhibitorima kinaza ovisnih o ciklinu (CDK). Dodatna istraživanja genomike LGSOC-a, u cilju boljeg definiranja aktivacije genskih mutacija ukljuÄenih u karcinogenezu, neophodna su radi poboljÅ”anja prognoze ove zloÄudne bolesti
Ovarian Cancer
Karcinom jajnika glavni je uzrok smrtnosti
meÄu karcinomima ženskoga spolnog sustava. Ne postoje
rutinski testovi rane dijagnostike raka jajnika, a rano prepoznavanje
bolesti otežano je zbog oskudne simptomatologije.
Ukupna stopa preživljenja bolesnica od karcinoma jajnika
iznosi gotovo 50%, Ŕto je velik napredak u odnosu na rane
80-e godine kada je iznosila oko 35%, a može se zahvaliti
uvoÄenju paklitaksela u lijeÄenje.Ovarian cancer is the main reason of death
among gynecological cancers. There is no routine test for
early diagnosis of ovarian cancer and early detection of this
cancer is difficult because of lack of simptomatology. Overall
survival rate among patients with ovarian cancer is almost
50 % and it represents a significant increase of survival in the
last decade due the introduction of paclitaxel in the treatment
of advanced stages of ovarian carcinoma
Role of CDK4/6 inhibitors in metastatic hormon positive HER2 negative breast cancer treatment
Primjena inhibitora CDK4/6 u lijeÄenju hormonski ovisnoga metastatskog raka dojke negativnog na HER-2 dovela je do bitnog poboljÅ”anja kontrole bolesti, i to ponajprije znatnim produljenjem preživljenja bez progresije bolesti, uz prihvatljiv profil toksiÄnosti. Osnovno djelovanje inhibitora CDK4/6 jest odgaÄanje razvoja rezistencije na endokrinu terapiju, odnosno reverziju veÄ nastale rezistencije. Medijani preživljenja bez progresije bolesti kreÄu se oko 20 i viÅ”e mjeseci u prvoj liniji lijeÄenja i 10-ak mjeseci i viÅ”e u drugoj liniji.
U prvoj liniji lijeÄenja kombinirani su s aromataznim inhibitorima, a u drugoj s fulvestrantom. Produljenjem vremena bez napredovanja bolesti odgaÄa se primjena kemoterapije, a bolesnicama se osigurava bolja
kvaliteta života. Zbog svega navedenoga ovi lijekovi u kombinaciji s endokrinom terapijom nova su, visokovrijedna terapijska opcija u lijeÄenju metastatskog raka dojke. MeÄutim, ostaju brojna otvorena pitanja za svakodnevnu kliniÄku praksu kao Å”to su optimalan odabir bolesnica za prvolinijsko i drugolinijsko lijeÄenje, sekvenciranje drugih lijekova nakon progresije bolesti na inhibitore CDK4/6 te dostupnost i cijena lijeÄenja.Implementation of CDK4/6 inhibitors in metastatic hormone receptor positive, HER2 negative breast cancer treatment significantly improves progression free survival. CDK4/6 inhibitors are characterized
by favorable toxicity profile. CDK4/6 inhibitor administration delays and/or overcomes endocrine therapy resistance in metastatic breast cancer. CDK4/6 inhibitors were tested in both first line treatment in combination with aromatase inhibitors, and in second line treatment in combination with fulvestrant. Progression free survival longer than 20 months in the first and longer than 10 months in the second treatment
line has been achieved. Progression free survival prolongation may delay chemotherapy administration and consequently enable longer period with maintained quality of life. CDK4/6 inhibitors in combination with endocrine therapy represent a new valuable treatment option for metastatic hormone receptor positive HER2 negative breast cancer. However , many questions such as optimal patient selection as well as positioning of the CDK4/6 inhibitors and other endocrine therapy options during the course of metastatic disease treatment, remain unanswered. Furthermore, availability and cost of CDK4/6 inhibitors are also important issues
Ovarian Cancer
Karcinom jajnika glavni je uzrok smrtnosti
meÄu karcinomima ženskoga spolnog sustava. Ne postoje
rutinski testovi rane dijagnostike raka jajnika, a rano prepoznavanje
bolesti otežano je zbog oskudne simptomatologije.
Ukupna stopa preživljenja bolesnica od karcinoma jajnika
iznosi gotovo 50%, Ŕto je velik napredak u odnosu na rane
80-e godine kada je iznosila oko 35%, a može se zahvaliti
uvoÄenju paklitaksela u lijeÄenje.Ovarian cancer is the main reason of death
among gynecological cancers. There is no routine test for
early diagnosis of ovarian cancer and early detection of this
cancer is difficult because of lack of simptomatology. Overall
survival rate among patients with ovarian cancer is almost
50 % and it represents a significant increase of survival in the
last decade due the introduction of paclitaxel in the treatment
of advanced stages of ovarian carcinoma
Nasljedni karcinom dojke i jajnika - iskustva KliniÄkog bolniÄkog centra Split
Aim: To investigate the clinical and pathohistological tumor characteristics, treatment, and treatment outcomes in patients with hereditary breast and ovarian cancer who were diagnosed, treated, and monitored at the University Hospital of Split from October 1999 to April 2021.
Methods: The data were collected retrospectively from the medical history of 15 patients. They included the patientās age at diagnosis, family history of malignancies, histological subtype, grade, breast cancer immunophenotype, stage of disease, status and types of BRCA mutations, type of surgical and oncological treatment, the specifics of metachronous bilateral breast cancers, the specifics of synchronous breast and ovarian cancers, and the outcome of treatment through overall survival (OS).
Results: The median age of patients at the time of diagnosis of breast cancer was 53 years, and for ovarian cancer it was 56 years. A positive family history was confirmed in 13 patients (87%). All ovarian cancer patients had a high-grade serous histologic type, most often diagnosed in FIGO stages III and IV. Breast cancers were most commonly diagnosed in stages IA and IIA, with equally represented triple-negative and luminal immunophenotypes. The most common mutation was BRCA1 c.5266dup. The median OS of our patients was not reached.
Conclusion: The clinical features of patients, pathohistological characteristics of tumors, and treatment outcomes in our study population are comparable with reports in the literature, respecting the specifics of different nations and races.Cilj: Istražiti kliniÄke osobitosti, patohistoloÅ”ke karakteristike tumora, naÄin i ishode lijeÄenja bolesnica s nasljednim karcinomom dojke i jajnika koje su dijagnosticirane, lijeÄene i praÄene u KliniÄkom bolniÄkom centru Split od listopada 1999. do travnja 2021. godine.
Metode: Podatci su prikupljeni retrospektivno iz povijesti bolesti 15 bolesnica. UkljuÄivali su dob bolesnica kod dijagnoze bolesti, obiteljsku anamnezu za zloÄudne bolesti, histoloÅ”ki podtip, gradus, imunofenotip karcinoma dojke, stadij bolesti, status i tip BRCA mutacija, osobitosti kirurÅ”kog i onkoloÅ”kog lijeÄenja, specifiÄnosti metakrono nastalih bilateralnih karcinoma dojke, specifiÄnosti sinkrono nastalih karcinoma dojke i jajnika te ishod lijeÄenja kroz ukupno preživljenje.
Rezultati: Medijan dobi bolesnica u trenutku dijagnoze raka dojke bio je 53 godine, a za karcinom jajnika 56 godina. Pozitivna obiteljska anamneza potvrÄena je u 13 (87%) bolesnica. Karcinom jajnika je kod svih bolesnica bio seroznog papilarnog histoloÅ”kog podtipa visokog gradusa i najÄeÅ”Äe dijagnosticiran u FIGO stadiju III i IV. Karcinom dojke je najÄeÅ”Äe dijagnosticiran u stadiju IA i IIA, jednake zastupljenosti trostruko negativnog i luminalnog imunofenotipa. NajÄeÅ”Äa mutacija je bila BRCA1 c.5266dup. Medijan ukupnog preživljenja naÅ”ih bolesnica nije dosegnut.
ZakljuÄak: KliniÄke osobitosti bolesnica, patohistoloÅ”ke karakteristike tumora kao i ishodi lijeÄenja u naÅ”oj studijskoj populaciji su usporedivi s izvjeÅ”Äima iz literature, respektirajuÄi specifiÄnosti razliÄitih naroda i rasa
KliniÄke preporuke za dijagnozu, lijeÄenje i praÄenje bolesnika oboljelih od raka nepoznata primarnog podrijetla [Clinical recommendations for diagnosis, treatment and monitoring of patients with cancer of unknown primary site]
Cancer of unknown primary (CUP) site comprises very heterogeneous group of various malignant tumors presented in metastatic phase of the disease. Diagnosis is set when primary site remains unidentified after a thorough diagnostic evaluation in patients with histologically proven malignant metastatic disease. Despite poor prognosis in most patients, favorable prognostic clinical entities have been recognized constituting the most important group of patients for oncological treatment. The following text presents the clinical guidelines in order to standardize the diagnosis, treatment and follow-up of patients with cancer of unknown primary site in the Republic of Croatia
CLINICAL RECOMMENDATIONS FOR DIAGNOSIS, TREATMENT AND MONITORING OF PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE
Rak nepoznata primarnog podrijetla obuhvaÄa vrlo heterogenu skupinu razliÄitih malignih tumora koji se prezentiraju u metastatskoj fazi bolesti. Dijagnoza se postavlja na temelju patohistoloÅ”ke potvrde maligne bolesti uz nemoguÄnost dokaza postojanja primarnog tumora nijednom dostupnom dijagnostiÄkom metodom. Iako je opÄenito loÅ”e prognoze, prepoznati su prognostiÄki povoljni kliniÄki entiteti koji Äine temeljnu skupinu bolesnika za aktivno onkoloÅ”ko lijeÄenje. U tekstu koji slijedi sadržane su kliniÄke upute s ciljem standardizacije dijagnostiÄkih postupaka, lijeÄenja i praÄenja bolesnika s nepoznatim primarnim rakom u Republici Hrvatskoj.Cancer of unknown primary (CUP) site comprises very heterogeneous group of various malignant tumors presented in metastatic phase of the disease. Diagnosis is set when primary site remains unidentified after a thorough diagnostic evaluation in patients with histologically proven malignant metastatic disease. Despite poor prognosis in most patients, favorable prognostic clinical entities have been recognized constituting the most important group of patients for oncological treatment. The following text presents the clinical guidelines in order to standardize the diagnosis, treatment and follow-up of patients with cancer of unknown primary site in the Republic of Croatia
KliniÄke preporuke za dijagnozu, lijeÄenje i praÄenje bolesnika oboljelih od raka nepoznata primarnog podrijetla [Clinical recommendations for diagnosis, treatment and monitoring of patients with cancer of unknown primary site]
Cancer of unknown primary (CUP) site comprises very heterogeneous group of various malignant tumors presented in metastatic phase of the disease. Diagnosis is set when primary site remains unidentified after a thorough diagnostic evaluation in patients with histologically proven malignant metastatic disease. Despite poor prognosis in most patients, favorable prognostic clinical entities have been recognized constituting the most important group of patients for oncological treatment. The following text presents the clinical guidelines in order to standardize the diagnosis, treatment and follow-up of patients with cancer of unknown primary site in the Republic of Croatia
CLINICAL RECOMMENDATIONS FOR DIAGNOSIS, TREATMENT AND MONITORING OF PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE
Rak nepoznata primarnog podrijetla obuhvaÄa vrlo heterogenu skupinu razliÄitih malignih tumora koji se prezentiraju u metastatskoj fazi bolesti. Dijagnoza se postavlja na temelju patohistoloÅ”ke potvrde maligne bolesti uz nemoguÄnost dokaza postojanja primarnog tumora nijednom dostupnom dijagnostiÄkom metodom. Iako je opÄenito loÅ”e prognoze, prepoznati su prognostiÄki povoljni kliniÄki entiteti koji Äine temeljnu skupinu bolesnika za aktivno onkoloÅ”ko lijeÄenje. U tekstu koji slijedi sadržane su kliniÄke upute s ciljem standardizacije dijagnostiÄkih postupaka, lijeÄenja i praÄenja bolesnika s nepoznatim primarnim rakom u Republici Hrvatskoj.Cancer of unknown primary (CUP) site comprises very heterogeneous group of various malignant tumors presented in metastatic phase of the disease. Diagnosis is set when primary site remains unidentified after a thorough diagnostic evaluation in patients with histologically proven malignant metastatic disease. Despite poor prognosis in most patients, favorable prognostic clinical entities have been recognized constituting the most important group of patients for oncological treatment. The following text presents the clinical guidelines in order to standardize the diagnosis, treatment and follow-up of patients with cancer of unknown primary site in the Republic of Croatia